Literature DB >> 22687336

A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity.

Sarah A Hiles1, Amanda L Baker, Theo de Malmanche, John Attia.   

Abstract

Epidemiological evidence for the inflammatory hypothesis of depression is largely cross-sectional; people with depression have elevated levels of circulating pro-inflammatory markers compared to people without depression. The limitation of cross sectional research is the potential for extraneous factors to influence observed effects. The purpose of this meta-analysis of cross-sectional studies of interleukin(IL)-6 and IL-10 in people with and without depression is to provide a targeted analysis of potential moderator factors relating to the diagnosis of depression and to physical and psychiatric comorbidity. Electronic searches of Embase and Medline databases were conducted using subject headings "interleukin-6" or "interleukin-10" and those relating to depression. Studies were included if they measured circulating marker levels in serum or plasma in a group of people with and without depressive symptoms (99 studies for IL-6, 19 studies for IL-10). IL-6 was elevated in depressed compared to non-depressed groups (d = 0.46, 99% CI 0.34 to 0.58, I(2) = 85.9%). This effect was larger in subgroups where depressive disorders were diagnosed compared to those with only depressive symptoms via standardized inventory, and subgroups where participants were recruited from inpatient or outpatient settings compared to the general community. The effect was also larger in those who were not selected for a particular comorbidity compared to those selected for cardiovascular disease. IL-10 effect size was not significant (d = -0.31, 99% CI -0.95 to 0.32, I(2) = 94.1%) which was not accounted for in subgroup analyses or meta-regression, indicating there is not a global elevation in cytokines. These data highlight that comorbidity and behavioral aspects of depression need to be measured and controlled in future prospective and experimental research testing the inflammatory hypothesis of depression.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22687336     DOI: 10.1016/j.bbi.2012.06.001

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  104 in total

1.  Rapid Regulation of Depression-Associated Genes in a New Mouse Model Mimicking Interferon-α-Related Depression in Hepatitis C Virus Infection.

Authors:  Carolina Hoyo-Becerra; Zijian Liu; Jinghong Yao; Britta Kaltwasser; Guido Gerken; Dirk M Hermann; Joerg F Schlaak
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

2.  The role of inflammatory markers in explaining the association between depression and cardiovascular hospitalisations.

Authors:  Sarah A Hiles; Amanda L Baker; Theo de Malmanche; Mark McEvoy; Michael Boyle; John Attia
Journal:  J Behav Med       Date:  2015-04-03

3.  Circulating versus lipopolysaccharide-induced inflammatory markers as correlates of subthreshold depressive symptoms in older adults.

Authors:  S Melanie Lee; Silena Te; Elizabeth C Breen; Richard Olmstead; Michael R Irwin; Joshua H Cho
Journal:  World J Biol Psychiatry       Date:  2019-10-09       Impact factor: 4.132

4.  Neuroinflammation in psychiatric disorders: An introductory primer.

Authors:  Geoffrey A Dunn; Jennifer M Loftis; Elinor L Sullivan
Journal:  Pharmacol Biochem Behav       Date:  2020-07-01       Impact factor: 3.533

Review 5.  Potential Mechanisms Underlying the Therapeutic Effects of Electroconvulsive Therapy.

Authors:  Jiangling Jiang; Jijun Wang; Chunbo Li
Journal:  Neurosci Bull       Date:  2016-12-28       Impact factor: 5.203

6.  Targeting Oxidative Stress, Cytokines and Serotonin Interactions Via Indoleamine 2, 3 Dioxygenase by Coenzyme Q10: Role in Suppressing Depressive Like Behavior in Rats.

Authors:  Sally A Abuelezz; Nevien Hendawy; Yosra Magdy
Journal:  J Neuroimmune Pharmacol       Date:  2016-10-11       Impact factor: 4.147

7.  Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia.

Authors:  Harald Murck; Thomas Laughren; Femke Lamers; Rosalind Picard; Sebastian Walther; Donald Goff; Stephen Sainati
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

8.  A depressive phenotype induced by Bacille Calmette Guérin in 'susceptible' animals: sensitivity to antidepressants.

Authors:  Brian Platt; Janet Schulenberg; Nicole Klee; Maryam Nizami; Janet A Clark
Journal:  Psychopharmacology (Berl)       Date:  2012-11-21       Impact factor: 4.530

9.  Adversity in preschool-aged children: Effects on salivary interleukin-1β.

Authors:  Audrey R Tyrka; Stephanie H Parade; Thomas R Valentine; Nicole M Eslinger; Ronald Seifer
Journal:  Dev Psychopathol       Date:  2015-05

10.  Remitted depression and cognition in HIV: The role of cortisol and inflammation.

Authors:  Leah H Rubin; Scott A Langenecker; K Luan Phan; Sheila M Keating; Gretchen N Neigh; Kathleen M Weber; Pauline M Maki
Journal:  Psychoneuroendocrinology       Date:  2020-02-07       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.